

ASX Announcement | 17 March 2021
Visioneering Technologies (ASX:VTI)

Results of Special Meeting of Stockholders

Atlanta, Georgia, Tuesday, 16 March 2021 (Wednesday, 17 March 2021 Sydney time): US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, **Visioneering Technologies, Inc (ASX: VTI)** (**'Visioneering'** or **'the Company'**), announces the results of its Special Meeting of Stockholders held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of a poll.

Ends.

This release was authorized by the CEO, Stephen Snowdy, PhD

For more information, please contact:

Company
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: ssnowdy@vtivision.com

About Visioneering Technologies, Inc.

Visioneering Technologies, Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and Visioneering has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

To learn more, please visit: www.vtvision.com

Foreign ownership restrictions

Visioneering's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Any forward-looking statements are provided as a guide only and should not be relied upon as an indication or guarantee of future performance. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. You should not place undue reliance on forward-looking statements because they speak only as of the date when made, and are subject to change without notice. Given the current uncertainties regarding the on-going impact of the COVID-19 on the trading conditions impacting Visioneering, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with Visioneering's expectations or that the effect of future developments on Visioneering will be those anticipated. Actual results may differ materially from what is expressed in this presentation and investors are cautioned not to place undue reliance on the current trading outlook.

Visioneering does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Visioneering may not actually achieve the plans, projections or expectations disclosed in forward-looking statements.



Visioneering Technologies, Inc 2021 Special Meeting

Holder Voting Summary

Shares Issued and Outstanding: 993,277,625
Shares Voted: 605,990,638
Shares Voted (%): 61.01%

The aggregate number of securities for which proxy votes were received prior to the meeting and for each resolution, were the same as the aggregate number of securities voted on the poll and for each resolution for each poll.

All resolutions were decided by a poll.

Resolution	Vote type	Voted	Voted (%)	Result
1 Approval of the issue of CDIs and Options under Placement	For	132,553,687	99.44%	Carried
	Against	582,457	0.44%	
	Abstain	156,024	0.12%	
2 Approval of the issue of CDIs and Options to Thorney under Placement	For	132,620,386	99.49%	Carried
	Against	515,758	0.39%	
	Abstain	156,024	0.12%	
3 Approval of the issue of CDIs and Options under Security Purchase Plan	For	605,651,856	99.94%	Carried
	Against	182,758	0.03%	
	Abstain	156,024	0.03%	
4.1 Issue of Shares and Options to Dr. David J. Mazzo, Chair of the Company	For	603,619,499	99.80%	Carried
	Against	1,019,758	0.17%	
	Abstain	156,024	0.03%	
4.2 Issue of Shares and Options to Mr. Tom Dooley, Non-Executive Director of the Company	For	603,619,499	99.80%	Carried
	Against	1,019,758	0.17%	
	Abstain	156,024	0.03%	
4.3 Issue of Shares and Options to Mr. Andrew Silverberg, Non-Executive Director of the Company	For	603,619,499	99.80%	Carried
	Against	1,019,758	0.17%	
	Abstain	156,024	0.03%	
4.4 Issue of Shares and Options to Ms. Christine Van Heek, Non-Executive Director of the Company	For	603,353,451	99.80%	Carried
	Against	1,019,758	0.17%	
	Abstain	156,024	0.03%	
5.1 Issue of Options to Aurenda Partners Pty Ltd	For	604,748,157	99.79%	Carried
	Against	1,086,457	0.18%	
	Abstain	156,024	0.03%	
5.2 Issue of Options to Bell Potter Securities Limited	For	604,648,157	99.77%	Carried
	Against	1,186,457	0.20%	
	Abstain	156,024	0.03%	
6 Approval of increase in Authorised Capital	For	605,252,157	99.87%	Carried
	Against	582,457	0.10%	
	Abstain	156,024	0.03%	